Longevity Vision Fund

Longevity Vision Fund (LVF) is a venture capital firm based in New York City, founded by Sergey Young. The fund focuses on investing in technologies and companies that aim to extend healthy human lifespans and address the negative effects of aging. With a $100 million fund, LVF supports innovations in preventive medicine, early detection, medical technologies, artificial intelligence in healthcare, longevity therapies, and regenerative medicine. LVF's mission is to accelerate breakthroughs in longevity and make these advancements more accessible and affordable to the general public. Notable investments include Senda Biosciences, a company dedicated to developing treatments through its proprietary molecular platform. The fund is led by Sergey Young, a prominent figure in the longevity space with over 20 years of investment experience. Other key team members include Avetik Arakelyan, Sourav Sinha, and Kris Verburgh, who bring diverse expertise in healthcare, technology, and finance. LVF targets early-stage investments and partners with innovative companies worldwide, aiming to transform the life sciences and healthcare industries. They emphasize a long-term commitment to improving human health and promoting a healthier, longer life for everyone.